Young US FDA Office Of New Drug Policy Faces Regulatory Crucible In COVID-19
Created last year under the Office of New Drugs reorganization, ONDP works to promote regulatory consistency while fostering innovation – and reacting to unexpected challenges like the pandemic.
You may also be interested in...
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.
Keeping Track: US FDA Approves Zokinvy, Defers Liso-Cel, Declines ALKS 3831 And Zimhi; Two Biosimilars Filed
The latest drug developments news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track: Keytruda Adds TNBC Claim; Finerenone, Brincidofovir, HTX-011 Submitted; CRL For Supernus’ ADHD Drug
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker